PPT-Dolutegravir plus Rilpivirine as Maintenance Dual Therapy

SWORD1 and SWORD 2 Dolutegravir plus Rilpivirine as Maintenance Dual Therapy SWORD1 and SWORD2 Design Source Llibre JM et al Lancet 20183983949 Background Identical randomized multinational openlabel industrysponsored parallelgroup . The member receives Most diagnostic preventive care at NO cha rge Cosmetic treatment The following member payments apply when a participating General Dentist performs services Par ticipating Specialists are available at fees discounted off of the Machine Volume Theory of Operation Neonatal Volume Targeted Ventilation 11 Neonatal Ventilation Setup 12 Inspiratory vs Expiratory Tidal Volume References Output pulse duration and accuracy depend on external timing components and are therefore under user control for each application It is well suited for a broad variety of appli cations including pulse delay generators square wave gen erators long de (DURC). University of North Carolina at Greensboro. Scope of Presentation. T. he . goal of this presentation is to provide an awareness on the . dual . use dilemma as it relates to academic research. The . David Spach, MD. Clinical Director, Northwest AETC. Professor of Medicine, Division of Infectious Diseases. University of Washington. Last Updated: October 21, 2013. 2013 . Asilomar. Update. New Occupational . According to the global Aerospace Maintenance Chemical Market report published by Value Market Research, the market is expected to touch USD 9 BN by 2024, with a CAGR of 4.0% growing from USD 6.5 BN in 2017. https://www.valuemarketresearch.com/report/aerospace-maintenance-chemical-market New pricing agreement will speed up access to generic, dolutegravir (DTG)-based fixed dose combinations (FDCs) . HIV positive people in low- and middle-income countries including South Africa can be treated for around R900 (US $75 a year) . ACTIVITY CODE . TD342. Antiretroviral Medications: . What . you need to know. Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP. Associate Professor, Department of Pharmacy Practice. Every 2 Months for HIV Maintenance. . ATLAS-2M. IM Cabotegravir and IM . Rilpivirine. Every 2 Months for HIV Maintenance. ATLAS-2M Study. : Design. Source: Overton ET, et al. Lancet. 2020:396:1994-2005.. DUAL-GESIDA. Dual Maintenance ART with RTV-Boosted Darunavir + . Lamivudine. DUAL . GESIDA: . Study Design. Source: . Pulido. . F, . et al. . Clin Infect . Dis..  . 2017;65:2112-8.. DRV + RTV + 3TC. Dovato. ). Last Updated: November 28, 2022. Prepared by:. Brian R. Wood, MD. David H. Spach, MD. Dolutegravir-Lamivudine. Photograph courtesy of . ViiV. INSTI. NRTI. 50 mg. 300 mg. Dolutegravir-Lamivudine. FLAMINGO. Dolutegravir + 2 NRTIs versus Darunavir + RTV + 2 NRTIs . FLAMINGO: Study Design. Source: . Clotet. B, et al. . Lancet. 2014;383:2222-31. . Dolutegravir + . TDF-FTC or ABC-3TC. (n = 242). Darunavir + Ritonavir + . SPRING-2 Study. Dolutegravir. versus Raltegravir. SPRING-2: Design. Source: . Raffi. F, et al. Lancet. 2013;381:735-43.. Dolutegravir. : 50 mg QD. Fixed-dose NRTI backbone*. (n = 411). Raltegravir. Judith S. Currier, MD, MSc. Professor of Medicine. University of California Los Angeles. Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years:.